Precigen
From Wikipedia, the free encyclopedia
Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.
| |
| Nasdaq: PGEN Russell 2000 Component | |
| Industry | Biotechnology |
| Founded | May 21, 1998 |
| Headquarters | , US |
| Revenue | $91 million (2019)[1] |
Number of employees | 600 |
| Website | precigen |
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.[2][3] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.[4]
History
In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million.[5] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.[6][7] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.[8][9] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.[7]
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.